Business Trends: Pharmaceutical Technology - Understanding your Pharmaceutical Customer (Customer Focus)
| Publication Date | December 2007 |
|---|---|
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 65 |
| ISBN Number | not applicable |
| Product Code | DAT09594 |
Summary
Introduction
This Datamonitor study examines top business challenges, IT budget outlook, and spending priorities among pharmaceutical and biotechnology companies in the US, the UK, France, Germany, and India. It is based on the results of Datamonitor's Business Trends primary research, conducted in Q3 and Q4 2007, with a total of 150 life science companies.
Scope
- In-depth interviews with 150 pharmaceutical and biotechnology companies
- Geographic coverage includes: the US, the UK, France, Germany, and India
- The study focuses on the business challenges, IT budget outlook, and the degree to which the market has adopted EDC and SOA solutions
- Respondents included IT decision-makers such as CIOs and CTOs
Highlights
IT vendors targeting the life science market must demonstrate deep industry knowledge and have high expertise in their specialty product.
Companies in the life science industry must build and maintain their product pipeline to compete with generic drug manufacturers. To achieve this, companies are beginning to change their business models, albeit slow, and are investing more money into technology solutions.
Pharmaceutical and biotechnology companies have several goals that affect their IT strategies, including achieving or maintaining regulatory compliance, raising efficiency, and aligning IT with overall business objectives.
Reasons to Purchase
- Validate your market messaging and positioning in the life science industry
- Compare pharmaceutical and biotechnology IT purchasing plans across geographies
- Identify emerging areas of concern for pharmaceutical and biotechnology companies
Content
About this Product
Delivery Details
PDF:Delivered by email usually within 4 to 8 UK business hours.
PRINT/CD-ROM:Despatched within 1 to 2 working days.
Related Products
Recently Viewed Products
- AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment >>
- Sanofi-Aventis and Pfizer Stop Development of a Class of Anti-obesity drugs >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Have your Healthcare Costs Reduced with Personalized Healthcare >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















